Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice

Abstract

Neuroinflammation is one disease hallmark on the road to neurodegeneration in primary tauopathies. Thus, immunomodulation might be a suitable treatment strategy to delay or even prevent the occurrence of symptoms and thus relieve the burden for patients and caregivers. In recent years, the peroxisome proliferator-activated receptor γ (PPARγ) has received increasing attention as it is immediately involved in the regulation of the immune system and can be targeted by the anti-diabetic drug pioglitazone. Previous studies have shown significant immunomodulation in amyloid-β (Aβ) mouse models by pioglitazone. In this study, we performed long-term treatment over six months in P301S mice as a tauopathy model with either pioglitazone or placebo. We performed serial 18 kDa translocator protein positron-emission-tomography (TSPO-PET) imaging and terminal immunohistochemistry to assess microglial activation during treatment. Tau pathology was quantified via immunohistochemistry at the end of the study. Long-term pioglitazone treatment had no significant effect on TSPO-PET, immunohistochemistry read-outs of microglial activation, or tau pathology levels in P301S mice. Thus, we conclude that pioglitazone modifies the time course of Aβ-dependent microglial activation, but does not significantly modulate microglial activation in response to tau pathology.

Effects of antidiabetic agents on platelet characteristics with implications in Alzheimer's disease: Mendelian randomization and colocalization study

“…In a real-world study, TZD users were also found to have a significantly lower risk of developing various types of dementia compared to non-TZD users who received dual oral therapy [ 41 ]. At the same time, it is worth noting that a relatively small proportion of clinical and laboratory evidence on the efficacy of TZDs in treating AD currently shows mixed or neutral effects, suggesting that caution is needed when extrapolating our findings [ [42] , [43] , [44] ].…”

Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease

“…Another molecular mechanism through which PGZ works is the regulation of AKT/GSK3β activation, resulting in improved peripheral and central insulin sensitivity, increased Aβ42 degradation, and decreased Aβ accumulation in diet-induced insulin resistance rats [135]. Conversely, a study in which P301S mice used as tauopathy models were treated with either PGZ or placebo over 6 months showed us that PGZ only altered the time course of microglial activation but did not significantly affect microglial activation in response to tau [136]. A pilot study conducted in AD and MCI participants with T2DM improved both the cognition and metabolic profile of the participants in the PGZ group [137].…”